Phaseline

Companies › 4TEEN4 Pharmaceuticals

4TEEN4 Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AK1967 (Invobenitug also known as Procizumab)
DPP3 inhibition using humanized monoclonal antibody
DPP3Phase 1Shock, CardiogenicDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06832722AK1967 (Invobenitug also known as Procizumab)Phase 1Shock, CardiogenicOtherDec 2026

Targets

DPP3 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.